Lipid formulations of amphotericin

被引:13
|
作者
Botero, Martha C. [1 ]
Puentes-Herrera, Marcela [1 ]
Cortes, Jorge A. [2 ]
机构
[1] Univ Nacl Colombia, Fac Med, Dept Med Interna, Bogota, Colombia
[2] Univ Nacl Colombia, Grp Invest Enfermedades Infecciosas, Bogota, Colombia
来源
REVISTA CHILENA DE INFECTOLOGIA | 2014年 / 31卷 / 05期
关键词
Amphotericin B; fungemia; drug toxicity; histoplasmosis; aspergillosis; candidemia; candidiasis; invasive; cryptococcosis; zygomycosis; leishmaniasis; MULTICENTER RANDOMIZED-TRIAL; CLINICAL-PRACTICE GUIDELINES; INFECTIOUS-DISEASES SOCIETY; HEMATOLOGIC MALIGNANCIES; DOUBLE-BLIND; VISCERAL LEISHMANIASIS; INVASIVE ASPERGILLOSIS; ANTIFUNGAL THERAPY; SALVAGE THERAPY; B AMBISOME;
D O I
10.4067/S0716-10182014000500002
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Amphotericin B deoxycholate use has increased during the past years in parallel with the increase in the number of immunosuppressed patients suffering invasive fungal infections. This drug is associated with a high rate of side effects, especially renal toxicity. Lipid formulations (liposomal, lipid complex, colloidal suspension and the Indian liposomal formulation) have been developed, which share the same antifungal spectrum but differ in efficacy and toxicity. A review of amphotericin lipid formulations is presented, focusing on differences in efficacy and, especially renal toxicity. The main problem for use of these formulations in Latin America is their highcost.
引用
收藏
页码:518 / 527
页数:10
相关论文
共 50 条
  • [1] Lipid formulations of amphotericin B
    AlAbdely, H
    Revankar, S
    Graybill, JR
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 18 (03) : 289 - 299
  • [2] Lipid formulations of amphotericin B
    Hiemenz, JW
    Walsh, TJ
    JOURNAL OF LIPOSOME RESEARCH, 1998, 8 (04) : 443 - 467
  • [3] Lipid formulations of amphotericin B
    Janknegt, R
    vanEtten, EWM
    deMarie, S
    CURRENT OPINION IN INFECTIOUS DISEASES, 1996, 9 (06) : 403 - 406
  • [4] The lipid formulations of amphotericin B
    Herbrecht, R
    Natarajan-Amé, S
    Nivoix, Y
    Letscher-Bru, V
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (08) : 1277 - 1287
  • [5] Lipid formulations of amphotericin B
    Jones, E
    Goldman, M
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 1998, 65 (08) : 423 - 427
  • [6] Pharmacology of lipid formulations of amphotericin B
    Dix, SP
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1998, 7 : S8 - S15
  • [7] Amphotericin B and its lipid formulations
    Ritter, J
    MYCOSES, 2002, 45 : 34 - 38
  • [8] Overview of the lipid formulations of amphotericin B
    Dupont, B
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 : 31 - 36
  • [9] Biopharmaceutical aspects of lipid formulations of amphotericin B
    Storm, G
    vanEtten, E
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1997, 16 (01) : 64 - 73
  • [10] Levels of amphotericin B lipid formulations in ascites
    Weiler, Stefan
    Bellmann-Weiler, Rosa
    Dunzendorfer, Stefan
    Joannidis, Michael
    Bellmann, Romuald
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (05) : 1163 - 1164